TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27718143
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg per day (12h sampling)
Study: 27718143
Drug: Donepezil 10
Normalized name: donepezil 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil 10 mg per day (24h sampling)
Study: 15284371
Drug: Lutein supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein supplement
Study: 15284371
Drug: Lutein ester
Normalized name: lutein esters
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein ester supplement
Study: 10965395
Drug: Promethazine oral
Normalized name: promethazine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine oral syrup (50 mg, 10 mL)
Study: 10965395
Drug: Promethazine rectal
Normalized name: promethazine Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine rectal suppository (50 mg)
Study: 10965395
Drug: Promethazine rectal
Normalized name: promethazine Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine rectal suppository (two 12.5 mg)
Study: 10965395
Drug: Promethazine rectal
Normalized name: promethazine Rectal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Promethazine rectal suppository (25 mg)
Study: 10965395
Drug: All formulations
Normalized name: Novel Influenza-H1N1-09, all formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: All formulations (oral syrup and rectal suppositories)
Study: 10965395
Drug: Three suppository
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three suppository treatments
Study: 7701651
Drug: Empirical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical treatment strategy (group 2)
Study: 25486391
Drug: Treatment-as-usual Alcohol
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-as-usual Alcohol Diversion Program (ADP)
Study: 9050948
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose GH: 16 IU/m2/week
Study: 9050948
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose GH: 28 IU/m2/week
Study: 9050948
Drug: GH: 24
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH: 24 IU/m2/week + Oxa: 0.06 mg/kg/day
Study: 8466063
Drug: Ketorolac 30
Normalized name: ketorolac 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac 30 mg intramuscularly every 6 h after an initial dose of 60 mg
Study: 3532404
Drug: Pirprofen (rengasil)
Normalized name: Carprofen
DrugBank: Pirprofen (DB13722)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pirprofen (rengasil) combined with small doses of corticosteroids
Study: 26945321
Drug: Higher density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher density treatment
Study: 26945321
Drug: Lower density
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower density treatment
Study: 26945321
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment densities
Study: 25231953
Drug: Everolimus (EVE)
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus (EVE) 10 mg/day plus Exemestane (EXE) 25 mg/day
Study: 25231953
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) plus Exemestane (EXE) 25 mg/day
Study: 21164551
Drug: Marine collagen
Normalized name: marine collagen, soluble
DrugBank: Marine collagen, soluble (DB14246)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marine collagen peptides (MCPs) 13 g daily for 3 months
Study: 17645254
Drug: Combined auricular
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined auricular and body acupuncture treatment plus moving cupping on back‐shu points
Study: 10208997
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with low-dose heparin (70 U/kg initial bolus)
Study: 10208997
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with standard-dose heparin (100 U/kg initial bolus)
Study: 10208997
Drug: placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo with standard-dose heparin (100 U/kg initial bolus)
Study: 10208997
Drug: abciximab therapy
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab therapy
Study: 7790694
Drug: High Protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Protein diet (HP) at 1.5 g/kg body weight/day
Study: 7790694
Drug: Marginal Protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marginal Protein diet (MP) at 1.0 g/kg body weight/day
Study: 31142441
Drug: Empagliflozin (EMPA)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (EMPA) 10 mg
Study: 31142441
Drug: Empagliflozin (EMPA)
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin (EMPA) 25 mg
Study: 28196207
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 400 mg once daily (400 mg/d)
Study: 28196207
Drug: Imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Imatinib mesylate 800 mg twice daily (800 mg/d)
Study: 28196207
Drug: Imatinib as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib as sole therapy
Study: 28196207
Drug: Additional systemic
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional systemic agents
Study: 23340492
Drug: Dietary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary intervention (daily supplementation with 1200 mg n-3 LCPUFAs and dietary counseling to reduce arachidonic acid (AA) intake)
Study: 15245938
Drug: Concurrent gemcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent gemcitabine (initial dose 10 mg/m2, increased as tolerated) and radiotherapy (RT)
Study: 15245938
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of gemcitabine (greater than 20 mg/m2)
Study: 15245938
Drug: Patients who
Normalized name: MAYZENT 0.25mg Tablet Starter Pack (For Patients Who Will Receive The 2mg Maintenance Dosage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who experienced dose-limiting toxicity (DLT)
Study: 11403535
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitors (PPIs) for long-term management of H. pylori-negative ulcers
Study: 9678430
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron gluconate
Study: 9678430
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous iron
Study: 8048390
Drug: Chemotherapy (CT)
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CT) plus Radiotherapy (RT)
Study: 2659312
Drug: High energy
Normalized name: High energy formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: High energy food supplement of 3.31 MJ for the first 3 months of the 6-month intervention period.
Study: 18201641
Drug: Behavioral Internet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Internet Treatment (BIT)
Study: 11199864
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ISDN
Study: 3536397
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg ISDN
Study: 11199864
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg SR ISDN
Study: 11199864
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SR ISDN
Study: 11199864
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SR ISDN (3x dosing)
Study: 30854986
Drug: 2.7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g/d of DHA
Study: 30854986
Drug: 2.7 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.7 g/d of EPA
Study: 30854986
Drug: 3 g/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 g/d of maize oil
Study: 27593504
Drug: Fluticasone furoate
Normalized name: Fluticasone Furoate
DrugBank: Fluticasone furoate (DB08906)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fluticasone furoate (100 μg) and vilanterol (25 μg) once daily
Study: 22231020
Drug: High concentrate
Normalized name: A Mulsin High Concentrate 300,000unit Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: High concentrate (450 g/day)
Study: 22231020
Drug: Moderate concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate concentrate (300 g/day)
Study: 22231020
Drug: Low concentrate
Normalized name: NIACINAMIDE 2 g in 100 mL / ADENOSINE 0.04 g in 100 mL TOPICAL LIQUID [Hydrating all in one glow concentrate ampoule]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low concentrate (150 g/day)
Study: 20102936
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day for 48 hours before and 48 hours after contrast medium administration
Study: 18854539
Drug: High-dose B
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose B vitamin supplementation (5 mg/d of folate, 25 mg/d of vitamin B(6), 1 mg/d of vitamin B(12))
Study: 15892275
Drug: Shenmai Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenmai Injection (SMI) plus conventional western medicine
Study: 12592681
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medicine (Control)
Study: 10404806
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) replacement therapy, initial dose of 1-3 IU/m2 x day (9-27 microg/kg), tapered to 1.30+/−0.38 IU/m2 x day (11 g/kg)
Study: 7570327
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment regimens
Study: 2202385
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment with levodopa/carbidopa (Sinemet Plus)
Study: 6375890
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment and placebo
Study: 7196705
Drug: Hydroxyzine 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 100 mg IV
Study: 22456951
Drug: DEN (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEN (200 mg/kg body weight) followed by 2-acetylamino fluorine (150 mg/kg body weight)
Study: 21342217
Drug: Atazanavir/ritonavir (ATV/RTV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atazanavir/ritonavir (ATV/RTV) 300/100 mg every 24 h for 14 days
Study: 21342217
Drug: Atazanavir (ATV)
DrugBank: Atazanavir (DB01072)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Atazanavir (ATV) 400 mg every 24 h for 14 days
Study: 11113837
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (BF) alone
Study: 11113837
Drug: Biofeedback therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback therapy (BF) + oral laxatives (LAX)
Study: 8421417
Drug: Amoxicillin (three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (three times a day)
Study: 26871692
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (electrical stimulation plus laser therapy)
Study: 26871692
Drug: Laser group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser group (dose 4-6 J per point, 6 points at the knee joint)
Study: 24755192
Drug: m-TOR therapy
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-TOR therapy (SRL and EVL)
Study: 24755192
Drug: m-TOR therapy
Normalized name: m-phenylenediamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: m-TOR therapy
Study: 21302489
Drug: Shaogen Decoction
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shaogen Decoction (SGD) administered 10 mL, thrice a day, increased to every 2 hours if 2nd or over 2nd grade ARE occurred.
Study: 21302489
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with antibiotics (cefuroxime 4.5 g) and hormone (dexamethasone 5 mg) by intravenous infusion for 7 days.
Study: 18394624
Drug: Lanolin eye
Normalized name: Lanolin
DrugBank: Lanolin (DB11112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanolin eye ointment (Duratears)
Study: 11550964
Drug: Leflunomide 20
Normalized name: leflunomide 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leflunomide 20 mg/day
Study: 9663720
Drug: Budesonide 9
Normalized name: budesonide 9 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 9 mg for 10 weeks
Study: 9663720
Drug: Methylprednisolone 32
Normalized name: methylprednisolone 32 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 32 mg for 3 weeks with tapering
Study: 18048820
Drug: Oral minocycline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral minocycline
Study: 3065267
Drug: Topical tetracycline
Normalized name: TETRACYCLINE HYDROCHLORIDE 30 mg in 1 mL TOPICAL SPRAY [Tetracyte Topical Tetracycline Hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical tetracycline ointment
Study: 28512843
Drug: New brightening
Approvals — FDA: no, EMA: no, PMDA: no
Description: New brightening complex cream containing niacinamide, tranexamic acid, oxyresveratrol, glutathione disulfide, and linoleic acid applied on the face two times per day for 12 weeks
Study: 28512843
Drug: New brightening
Approvals — FDA: no, EMA: no, PMDA: no
Description: New brightening complex cream
Study: 26387055
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (400 mcg)
Study: 26387055
Drug: Intra-arterial nitroglycerin
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial nitroglycerin (200 mcg)
Study: 26387055
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (400 mcg) in patients < 1.65 m height
Study: 26387055
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (400 mcg) in patients with diabetes
Study: 26387055
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin (400 mcg) in smokers
Study: 23107873
Drug: S18886 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: S18886 30 mg/d for 5 days
Study: 21959813
Drug: Morphine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (2 or 4 mg)
Study: 21959813
Drug: Pethidine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (25 or 50 mg)
Study: 21959813
Drug: Fentanyl (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (50 μg)
Study: 21959813
Drug: All opioids
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All opioids (morphine, pethidine, fentanyl)
Study: 18294482
Drug: Dalteparin 120
Normalized name: dalteparin
DrugBank: Dalteparin (DB06779)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalteparin 120 IU/kg s.c. (maximum 10,000 IU) twice daily for 5 to 7 days in hospital, followed by placebo for 3 months (n = 285)
Study: 18294482
Drug: Sex- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex- and weight-adjusted doses of dalteparin (5000 or 7500 IU) twice daily for 3 months (n = 270)
Study: 10624992
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% (20 mL)
Study: 10624992
Drug: Bupivacaine 0.5%
Normalized name: BUPivacaine 0.5% injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.5% (20 mL)
Study: 31736123
Drug: Single Ablative
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Ablative Fractional Resurfacing Laser Treatment (FLR)
Study: 29033355
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia tramadol + SAPB (Group S)
Study: 29033355
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia tramadol (Group T)
Study: 27067393
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac 3% gel
Study: 27067393
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (diclofenac and calcitriol)
Study: 27067393
Drug: Topical calcitriol
Normalized name: calcitriol Topical Ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical calcitriol 3 μg/g ointment
Study: 22652344
Drug: ALVAC-HIV (vCP1521)
Normalized name: HIV Integrase Inhibitor
DrugBank: HIV Integrase Inhibitor (DB16114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC-HIV (vCP1521) and AIDSVAX B/E vaccine regimen
Study: 18783504
Drug: bupropion sustained-release
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bupropion sustained-release (SR) treatment
Study: 17057382
Drug: placebo pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill
Study: 15629356
Drug: DTPa-IPV/Hib and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV/Hib and HBV vaccines administered separately
Study: 31814044
Drug: Magnesium supplementation
Normalized name: Magnesium
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium supplementation (intravenous magnesium sulfate to maintain serum magnesium level around 3 mg/dL for 3 days)
Study: 29702040
Drug: Combination diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination diet (whole grains and fruits and vegetables)
Study: 27104803
Drug: Continuation cognitive
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation cognitive therapy (C-CT)
Study: 27104803
Drug: Pill placebo
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pill placebo (PBO) plus clinical management
Study: 22134624
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg minodronate once a day
Study: 17205494
Drug: Multilayer compression
Normalized name: zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilayer compression treatment with ULSA score of 50 or less
Study: 17205494
Drug: Multilayer compression
Normalized name: zileuton
DrugBank: Zileuton (DB00744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multilayer compression treatment with ULSA score of greater than 50
Study: 11193270
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (Epidural bupivacaine and Intravenous morphine)
Study: 1606457
Drug: Anticoagulant agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulant agents
Study: 31590926
Drug: Pharmacist-led care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacist-led care coordination during transition from inpatient to community setting with follow-up medication therapy management (MTM) by community pharmacists.
Study: 31590926
Drug: Medication therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication therapy management (MTM) provided by community pharmacists postdischarge.
Study: 28850471
Drug: 2mg morphine
Normalized name: morphine sulfate 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg morphine into inflamed tissue
Study: 28850471
Drug: 2mg morphine
Normalized name: morphine sulfate 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg morphine into non-inflamed tissue
Study: 28850471
Drug: Time to
Normalized name: Overtime Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time to first analgesic intake
Study: 20427088
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab + prompt laser
Study: 20427088
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg ranibizumab + deferred laser
Study: 20427088
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg triamcinolone + prompt laser
Study: 20427088
Drug: sham injection
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: sham injection + prompt laser
Study: 26248590
Drug: Insulin pump
Normalized name: insulin pump syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin pump therapy (CSII)
Study: 18227475
Drug: Long-acting insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting insulin analogs (glargine and detemir)
Study: 10560985
Drug: Crinone vaginal
Normalized name: Crinone Vaginal Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crinone vaginal progesterone gel (90 mg once daily)
Study: 8904262
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia with nitrous oxide and isoflurane
Study: 31689480
Drug: Chinese herbal
Normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal medicines (Fufang Chuanxiong Capsule and Xinyue Capsule)
Study: 31689480
Drug: Western medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine standard therapy
Study: 24565955
Drug: Atrasentan (bone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan (bone targeted endothelin-A receptor antagonist)
Study: 22316089
Drug: LGS-Off (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGS-Off (continued insulin delivery regardless of SG value)
Study: 10521964
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg every 3 hours